Abstract
In this issue of The Lancet Global Health, Emily Li and colleagues1 outline an innovative approach to adapting the current WHO schistosomiasis guidelines for morbidity control and elimination as a public health problem. The authors conclude that programmes can achieve their aims quicker if they undertake an early review of programme progress (after 2–3 years) and use the results to adapt their programmes. This adaptation can include increasing the frequency of praziquantel mass drug administration (MDA) and the possible addition of snail control.
Highlights
In this issue of The Lancet Global Health, Emily Li and colleagues[1] outline an innovative approach to adapting the current WHO schistosomiasis guidelines for morbidity control and elimination as a public health problem
The authors conclude that programmes can achieve their aims quicker if they undertake an early review of programme progress and use the results to adapt their programmes. This adaptation can include increasing the frequency of praziquantel mass drug administration (MDA) and the possible addition of snail control
Li and colleagues found that this strategy led to larger decreases in prevalence over fewer rounds of MDA
Summary
In this issue of The Lancet Global Health, Emily Li and colleagues[1] outline an innovative approach to adapting the current WHO schistosomiasis guidelines for morbidity control and elimination as a public health problem. The authors conclude that programmes can achieve their aims quicker if they undertake an early review of programme progress (after 2–3 years) and use the results to adapt their programmes. This adaptation can include increasing the frequency of praziquantel mass drug administration (MDA) and the possible addition of snail control.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
